Literature DB >> 11849195

Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions.

B R Ogutu1, C R J C Newton, J Crawley, S N Muchohi, G O Otieno, G Edwards, K Marsh, G O Kokwaro.   

Abstract

AIMS: Convulsions are a common complication of severe malaria in children and are associated with poor outcome. Diazepam is used to terminate convulsions but its pharmacokinetics and pharmacodynamics have not been studied in this group. Accordingly, we carried out a comparative study of the pharmacokinetics of intravenous (i.v.) and rectal (p.r.) diazepam.
METHODS: Twenty-five children with severe malaria and a convulsion lasting >5 min were studied. Sixteen children received diazepam intravenously (i.v.; 0.3 mg kg(-1)) and nine rectally (p.r.; 0.5 mg kg(-1)). Plasma diazepam concentrations were measured by reversed phase high-performance liquid chromatography. The duration of convulsions, depth of coma, respiratory and cardiovascular parameters were monitored.
RESULTS: Median maximum plasma diazepam concentrations of 634 (range 402-1507) ng ml(-1) and 423 (range 112-1953) ng ml(-1) were achieved at 5 and 25 min following i.v. and p.r. administration, respectively. All patients except three (one i.v. and two p.r.) achieved plasma diazepam concentration >200 ng ml(-1) within 5 min. Following p.r. administration, plasma diazepam concentrations were more variable than i.v. administration. A single dose of i.v. diazepam terminated convulsions in all children but in only 6/9 after p.r. administration. However, nine children treated with i.v. and all those treated with p.r. diazepam had a recurrence of convulsions occurring at median plasma diazepam concentrations of 157 (range: 67-169) and 172 (range: 74-393) ng ml(-1) , respectively. All the children in the i.v. and four in the PR diazepam group who had recurrence of convulsions required treatment. None of the children developed respiratory depression or hypotension.
CONCLUSIONS: Administration of diazepam i.v. or p.r. resulted in achievement of therapeutic concentrations of diazepam rapidly, without significant cardio-respiratory adverse effects. However, following p.r. administration, diazepam did not terminate all convulsions and plasma drug concentrations were more variable.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849195      PMCID: PMC1874558          DOI: 10.1046/j.0306-5251.2001.01529.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  35 in total

1.  Respiratory and cardiovascular effects in relation to plasma levels of midazolam and diazepam.

Authors:  M Sunzel; L Paalzow; L Berggren; I Eriksson
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

2.  Pharmacokinetic model for diazepam and its major metabolite desmethyldiazepam following diazepam administration.

Authors:  M L Jack; W A Colburn
Journal:  J Pharm Sci       Date:  1983-11       Impact factor: 3.534

3.  Delayed clearance of diazepam due to cimetidine.

Authors:  U Klotz; I Reimann
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

4.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

Review 5.  Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

6.  Comparison of the pharmacokinetics of diazepam after single and subchronic doses.

Authors:  U Klotz; K H Antonin; P R Bieck
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

7.  Effective short-term diazepam prophylaxis in febrile convulsions.

Authors:  F U Knudsen
Journal:  J Pediatr       Date:  1985-03       Impact factor: 4.406

8.  Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin.

Authors:  D M Shaner; S A McCurdy; M O Herring; A J Gabor
Journal:  Neurology       Date:  1988-02       Impact factor: 9.910

9.  Double-blind study of lorazepam and diazepam in status epilepticus.

Authors:  I E Leppik; A T Derivan; R W Homan; J Walker; R E Ramsay; B Patrick
Journal:  JAMA       Date:  1983-03-18       Impact factor: 56.272

10.  Diazepam effects and kinetics in Caucasians and Orientals.

Authors:  M M Ghoneim; K Korttila; C K Chiang; L Jacobs; R D Schoenwald; S P Mewaldt; K O Kayaba
Journal:  Clin Pharmacol Ther       Date:  1981-06       Impact factor: 6.875

View more
  16 in total

Review 1.  Diagnosis and management of the neurological complications of falciparum malaria.

Authors:  Saroj K Mishra; Charles R J C Newton
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

2.  Entomotoxicology in burnt bodies: a case of maternal filicide-suicide by fire.

Authors:  V Bugelli; L Papi; S Fornaro; F Stefanelli; S Chericoni; M Giusiani; S Vanin; C P Campobasso
Journal:  Int J Legal Med       Date:  2017-07-09       Impact factor: 2.686

Review 3.  Cerebral malaria: optimising management.

Authors:  Neema Mturi; Crispin O Musumba; Betty M Wamola; Bernhards R Ogutu; Charles R J C Newton
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

4.  Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus.

Authors:  Bernhards R Ogutu; Charles R J C Newton; Simon N Muchohi; Godfrey O Otieno; Geoffrey Edwards; William M Watkins; Gilbert O Kokwaro
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

5.  Predictors of anti-convulsant treatment failure in children presenting with malaria and prolonged seizures in Kampala, Uganda.

Authors:  Arthur Mpimbaza; Sarah G Staedke; Grace Ndeezi; Justus Byarugaba; Philip J Rosenthal
Journal:  Malar J       Date:  2009-06-29       Impact factor: 2.979

6.  Status epilepticus in resource-poor countries.

Authors:  Charles R J C Newton
Journal:  Epilepsia       Date:  2009-12       Impact factor: 5.864

7.  Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions.

Authors:  Gilbert O Kokwaro; Bernhards R Ogutu; Simon N Muchohi; Godfrey O Otieno; Charles R J C Newton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

8.  Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration.

Authors:  Bernhards R Ogutu; Charles R J C Newton; Simon N Muchohi; Godfrey O Otieno; Gilbert O Kokwaro
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

9.  Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions.

Authors:  Simon N Muchohi; Kenneth Obiero; Charles R J C Newton; Bernhards R Ogutu; Geoffrey Edwards; Gilbert O Kokwaro
Journal:  Br J Clin Pharmacol       Date:  2007-07-17       Impact factor: 4.335

10.  Risk factors associated with death in in-hospital pediatric convulsive status epilepticus.

Authors:  Tobias Loddenkemper; Tanvir U Syed; Sriram Ramgopal; Deepak Gulati; Sikawat Thanaviratananich; Sanjeev V Kothare; Amer Alshekhlee; Mohamad Z Koubeissi
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.